A US economic model estimates that comprehensive sequencing directs more patients to targeted therapies with minimal budget impact compared with 50-gene panels....
An observational study in 102 patients reports a 57.4% pathological complete response with CT-P6 plus pertuzumab and chemotherapy, with no signs of immunogenicity....
An analysis of the plasmaMATCH trial shows that low circulating tumor DNA levels and their disappearance during treatment are linked to better responses....
A retrospective analysis of 8,825 patients from GEICAM studies places 10-year invasive disease-free survival at 73.8% for the intermediate-risk group....
The PHERGain-2 study reaches a 59.6% pathological complete response with trastuzumab and pertuzumab without chemotherapy in selected early HER2+ patients....
A study in 477 patients confirms that more than 20% tumor-infiltrating lymphocytes predicts better chemotherapy response, and that their form adds information....
Genomic analysis of the SOLAR-1 trial shows that patients with FGFR1 or FGFR2 alterations or low mutational burden gain more from alpelisib plus fulvestrant....
A phase I trial with ten older or frail patients suggests that stereotactic ablative radiotherapy in five fractions, up to 40 Gy, is well tolerated and does not reach the maximum tolerated dose....
A preliminary Spanish report finds that all nine patients with severe sacituzumab govitecan toxicity carried the UGT1A1*28 allele, and advocates preventive genotyping....
The Spanish PROCURE project, with 292 patients, finds that UGT1A1 genotypes do not explain the adverse effects of trastuzumab-deruxtecan in advanced breast cancer....
A retrospective analysis at Hospital 12 de Octubre shows excellent outcomes in intermediate-risk PAM50 patients, yet relapses that call for refining risk stratification....
The Spanish SOLTI-1303 PATRICIA trial shows the triplet improves progression-free survival versus standard care in HER2-positive luminal tumours....